Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ).
Shanghai Junshi Biosciences Co., Ltd. announced that its chairman, Mr. Xiong Jun, plans to increase his shareholding in the company by at least RMB100 million over the next 12 months, with a significant portion allocated to A shares. As of now, Mr. Xiong has already acquired 100,000 A shares, representing 0.01% of the company’s total share capital, through the Shanghai Stock Exchange. This move is aimed at strengthening the company’s market position and reflects confidence in its future growth prospects, although it is subject to market conditions and other unforeseen risks.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in China, focusing on the research, development, and commercialization of innovative therapies. The company is primarily engaged in the production of drugs for cancer, autoimmune, and metabolic diseases, with a strong market presence in both domestic and international markets.
Average Trading Volume: 4,995,191
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.81B
Learn more about 1877 stock on TipRanks’ Stock Analysis page.